Elicio Therapeutics logo
Elicio Therapeutics
ELTX | NASDAQ
Chart Builder DCF Calculator
$1.48
-$0.02 (-1.33%)
At close: Nov 16, 2026, 4:00 PM ET
$1.48
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Elicio Therapeutics Company Profile

Company profile explained

Company Profile

Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.

Key Executives

Name Position
Robert T. Connelly Chief Executive Officer, President & Director
Marc J. Wolfgang Chief Technology Officer
Allen Richard Nissenson FACP Founder & Independent Director
Christopher Haqq Executive Vice President, Head of Research & Development and Chief Medical Officer
Darrell J. Irvine Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board
Esther Welkowsky Senior Vice President of Clinical Development
Joy Seymour Senior VP & Head of Regulatory Affairs
Megan C. Filoon General Counsel, Secretary & Compliance Officer
Peter DeMuth Chief Scientific Officer
Preetam Shah Chief Strategy & Financial Officer and Treasurer
Thian Kheoh Senior Vice President of Biometrics

Latest SEC Filings

Date Type Title
Oct 09, 2026 DEF 14A Filing
Sep 14, 2026 8-K Current Report
Sep 02, 2026 4 Filing
Sep 02, 2026 4 Filing
Sep 02, 2026 4 Filing
Sep 02, 2026 4 Filing
Sep 02, 2026 4 Filing
Sep 02, 2026 4 Filing
Sep 02, 2026 4 Filing
Aug 13, 2026 10-Q Quarterly Report
View All SEC Filings ➞
Elicio Therapeutics
Elicio Therapeutics logo
Country United States
IPO Date Feb 5, 2021
Industry Biotechnology
Sector Healthcare
Employees 33
CEO Robert T. Connelly

Contact Details

451 D Street Boston, Massachusetts 02210 United States

Stock Details

Ticker Symbol ELTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001601485
CUSIP Number 28657F103
ISIN Number US28657F1030
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.